医学
神经母细胞瘤
居里
内科学
肿瘤科
临床研究阶段
完全缓解
临床试验
化疗
核医学
小儿肿瘤学
放射科
作者
Zitong Zhang,Hui Wang,Hongming Zhuang,Feize Li,Chunyang Nong,Yue Kang,Xia Guo,Rong Tian
标识
DOI:10.1097/rlu.0000000000006630
摘要
An 11-year-old boy with relapsed, poorly differentiated left adrenal neuroblastoma presented with multiple bone metastases, demonstrated by an 18 F-MFBG PET/CT with a Curie score of 4, despite prior multimodal therapy. He was subsequently enrolled in a phase 1 dose-escalation trial of 211 At-MABG-targeted alpha therapy. Follow-up 18 F-MFBG PET/CT revealed the resolution of most lesions and markedly decreased tracer uptake at the residual site, reducing his posttreatment Curie score to 1. This case highlights the therapeutic potential, safety, and feasibility of repeated, low-dose 211 At-MABG-targeted alpha therapy for pediatric relapsed neuroblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI